Download PDF
Thromb Haemost 2012; 108(03): 405-406
DOI: 10.1160/TH12-06-0438
Invited Editorial Focus
Schattauer GmbH

Indirect comparison studies – are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation

Flemming Skjøth
1   Department of Cardiology, Aalborg AF Study Group, Cardiovascular Research Centre, Aarhus University Hospital, Denmark
,
Torben Bjerregaard Larsen
1   Department of Cardiology, Aalborg AF Study Group, Cardiovascular Research Centre, Aarhus University Hospital, Denmark
2   Thrombosis Research Unit, Faculty of Medicine, Aalborg University, Aalborg, Denmark
,
Lars Hvilsted Rasmussen
1   Department of Cardiology, Aalborg AF Study Group, Cardiovascular Research Centre, Aarhus University Hospital, Denmark
2   Thrombosis Research Unit, Faculty of Medicine, Aalborg University, Aalborg, Denmark
› Author Affiliations
Further Information

Publication History

Received: 27 June 2012

Accepted: 27 June 2012

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

Editorial Focus on ► Mantha, Ansell. Thromb Haemost 2012; 108: 476-484.

 

  • References

  • 1 Kirchhof P, Lip GY, Van Gelder IC. et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106: 1012-1019.
    PubMedGoogle Scholar
  • 2 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?. Thromb Haemost 2011; 105: 574-578.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Mantha S, Ansel J. An Indirect Comparison of Dabigatran, Rivaroxaban and Apixaban for Atrial Fibrillation. Thromb Haemost 2012; 108: 476-484.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Kakkar AK, Mueller I, Bassand JP. et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163: 13-19.
    CrossrefPubMedGoogle Scholar
  • 6 Bucher HC, Guyatt GH, Griffith LE. et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
    CrossrefPubMedGoogle Scholar
  • 7 Lip GYH, Larsen TB, Skjoth F. et al. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012 epub ahead of print.
    PubMedGoogle Scholar
  • 8 Song F, Loke YK, Walsh T. et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. Br Med J 2009; 338: 1147-1154.
    CrossrefPubMedGoogle Scholar
  • 9 Edwards SJ, Clarke MJ, Wordsworth S. et al. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract 2009; 63: 841-854.
    CrossrefPubMedGoogle Scholar
  • 10 Roskell NS, Lip GY, Noack H. et al. Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2011; 105: 1-10.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Jansen JP, Fleurence R, Devine B. et al. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 2011; 14: 417-428.
    CrossrefPubMedGoogle Scholar
  • 12 Hoaglin DC, Hawkins N, Jansen JP. et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14: 429-437.
    CrossrefPubMedGoogle Scholar
  • 13 Gorin L, Fauchier L, Nonin E. et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010; 103: 833-840.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Gallagher AM, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?. Thromb Haemost 2010; 104: 45-48.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Keogh C, Wallace E, Dillon C. et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538.
    PubMedGoogle Scholar
  • 17 Olesen JB, Torp-Pedersen C, Hansen ML. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
    Article in Thieme ConnectPubMedGoogle Scholar